Mobile website
Review
Recent progress of HER-2/neu cancer vaccines
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Abstract Overexpression of HER-2/neu oncogene is a frequent molecular event in multiple human cancers, including in approximately 30% of all primary breast cancer case. The humanized anti-HER-2 monoclonal antibody, trastuzumab (also named as herceptin), has been proven to be effective in patients with HER-2-associated metastatic breast cancer since 1990s. Great progress has been made in developing various vaccines targeting HER-2, including peptide vaccines, protein vaccines, cell vaccines, dendritic cell-associated vaccines, and DNA vaccines. For example, peptide E75 (p369-399) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) has been shown effective for HLA-A2(+)/A3(+) stage Ⅱ breast cancer patients, and HER-2-targeted DNA vaccine has already entered clinical trials. They might be important ways for treatment of breast cancer. Anyhow, there are still a lot of problems need to be addressed before their application in clinical practice.
Keywords:
Project Supported:
Project supported by the National High Technology Research and Development Program (863 Program) of China (No. 2007AA02A249)
Clc Number:
